If You Invested in Lexaria Bioscience Corp. Warrant (LEXXW)
See the LEXXW overviewWhat $1,000 or $10,000 in LEXXW Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Jan 12, 2021 |
|---|---|---|---|---|
| $1,000 | $1.85 -99.82% | $0.95 -99.90% | — | $1.13 -99.89% |
| $10,000 | $18 -99.82% | $9.52 -99.90% | — | $11 -99.89% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-01-13. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for LEXXW$1,000 Investment Over Time
LEXXW vs S&P 500Year-by-Year Returns
LEXXW annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021Jan 12 to Dec 31 | $1.0599 | $1.50 | +41.5% | +41.5% |
| 2022 | $1.50 | $0.3999 | -73.3% | -62.3% |
| 2023 | $0.3999 | $0.45 | +12.5% | -57.5% |
| 2024Dec 29, 2023 to Dec 30 | $0.45 | $0.7641 | +69.8% | -27.9% |
| 2025Dec 30, 2024 to Dec 31 | $0.7641 | $0.0042 | -99.5% | -99.6% |
| 2026Dec 31, 2025 to Jan 13 | $0.0042 | $0.0012 | -71.4% | -99.9% |
About Lexaria Bioscience Corp. Warrant
NASDAQ
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) is described in its public communications as a global innovator in drug delivery platforms. The company focuses on its patented DehydraTECH™ formulation and processing platform technology, which is designed to improve the way a variety of drugs enter the bloodstream through oral delivery. According to multiple company news releases, DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side effects, and deliver some drugs more effectively across the blood brain barrier.
Lexaria operates within the pharmaceutical and biotechnology ecosystem while being classified under medicinal and botanical manufacturing in the manufacturing sector. Its business activities, as outlined in press releases, center on research and development of DehydraTECH-enabled formulations, clinical and pre-clinical studies, and the pursuit of licensing and partnering opportunities with pharmaceutical and biotechnology companies. The company also operates a licensed in-house research laboratory and reports holding an intellectual property portfolio with more than 50 granted patents worldwide, with additional patents pending.
DehydraTECH Platform and Drug Delivery Focus
The core of Lexaria’s business model is its DehydraTECH drug delivery platform. Company disclosures state that DehydraTECH is a patented formulation and processing technology intended to improve oral delivery of drugs. Public statements emphasize three main attributes of the platform:
- Increasing bio-absorption of active pharmaceutical ingredients.
- Reducing side effects, including gastrointestinal adverse events in certain studies.
- Enhancing delivery of some drugs across the blood brain barrier.
Lexaria’s communications highlight that DehydraTECH is applied to a range of drug types. The company has reported work with glucagon-like peptide‑1 (GLP‑1) drugs such as semaglutide, tirzepatide, and liraglutide, as well as cannabidiol (CBD). These efforts are directed at oral delivery formats and are being evaluated in both human and animal studies.
Clinical and Pre-Clinical Programs
Based on recent news, Lexaria dedicates significant resources to research and development programs that evaluate DehydraTECH with established drugs. The company has described multiple human clinical studies and pre-clinical work, including:
- Human Pilot Studies involving GLP‑1 drugs such as tirzepatide and liraglutide, comparing DehydraTECH-processed oral formulations to injectable reference products.
- Phase 1b Study GLP‑1‑H24‑4 in Australia, a registered 12‑week chronic study with follow-up, which investigated several DehydraTECH formulations (including DehydraTECH‑CBD, DehydraTECH‑semaglutide, and DehydraTECH‑tirzepatide) relative to the oral GLP‑1 product Rybelsus® as a control.
- Rodent biodistribution studies using fluorescently tagged semaglutide to compare DehydraTECH‑processed compositions with conventional oral formulations.
Company-reported outcomes from these studies emphasize safety and tolerability of DehydraTECH formulations, reductions in total and gastrointestinal adverse events relative to control arms, and comparable performance on key efficacy parameters such as blood glucose, insulin, and certain body composition measures in defined settings. Lexaria also reports exploratory findings related to blood pressure reductions in a DehydraTECH‑CBD arm and brain biodistribution trends in animal studies.
Therapeutic Areas and R&D Priorities
In strategic updates, Lexaria identifies several therapeutic areas where DehydraTECH-based formulations are being explored or protected by patents. These include:
- Diabetes control and weight loss, particularly through GLP‑1 drug formulations.
- Hypertension, including a program to investigate DehydraTECH‑CBD for blood pressure reduction.
- Seizure disorders.
- Anti-viral applications.
- Hormone replacement and other pharmaceutical applications.
The company notes that its patents cover compositions and methods for treating conditions such as epilepsy, diabetes, hypertension, and viral infections, as well as food and beverage compositions infused with lipophilic active agents. These disclosures indicate that Lexaria views DehydraTECH as a broad platform technology with potential applicability across multiple therapeutic categories, even though the development stage and regulatory status of individual programs vary.
Intellectual Property and Patents
Lexaria consistently highlights its intellectual property position as a key asset. In various news releases, the company reports holding more than 50 granted patents worldwide, with specific counts (such as 50, 54, or 56) cited at different times as new patents are issued. Recent patent grants mentioned include:
- Patents for compositions and methods for treating epilepsy.
- Patents for compositions and methods for treating diabetes.
- Patents covering food and beverage compositions infused with lipophilic active agents.
- Patents for enhanced delivery of antiviral agents.
These patents are part of broader patent families that, according to Lexaria, support its strategy of building long-term value around DehydraTECH-enabled formulations and potential licensing or partnering arrangements.
Partnerships and Material Transfer Agreement
Lexaria has disclosed a Material Transfer Agreement (MTA) with a pharmaceutical company, referred to as "PharmaCo," to evaluate DehydraTECH in a pre-clinical setting. The company reports that:
- The MTA was originally entered into in 2024 and later extended through April 30, 2026.
- Initial pre-clinical pharmacokinetic studies under the MTA were completed.
- PharmaCo requested access to the full dataset from Lexaria’s Australian human clinical study GLP‑1‑H24‑4 for review.
Lexaria characterizes the MTA as including a temporary exclusive license and as a framework for potential additional strategic planning discussions with PharmaCo’s human clinical development team. The outcome of these discussions is not specified in the available information, but the extension of the MTA indicates an ongoing evaluation relationship.
Capital Markets Activity and Use of Proceeds
Lexaria Bioscience Corp. is listed on Nasdaq under the symbols LEXX (common shares) and LEXXW (warrants). Company news releases describe several registered direct offerings of common stock, often accompanied by concurrent private placements of unregistered warrants. These financings are described as being priced at-the-market under Nasdaq rules.
Across multiple announcements, Lexaria states that the gross proceeds from these offerings are intended to be used to advance its research and development efforts, fund working capital, and support other general corporate purposes. In some cases, the company notes that the additional capital is expected to enable R&D and business development programs into future periods, including new or expanded clinical and pre-clinical work in the GLP‑1 sector and other areas of interest.
Business Development and Strategic Outreach
In a strategic update, Lexaria reports engaging a global life science business development advisory firm to support new business development activities. The company indicates that this engagement is intended to:
- Identify and pursue collaborative business opportunities with pharmaceutical and biotechnology companies.
- Expand outreach related to licensing and partnering discussions around DehydraTECH.
Lexaria notes that, due to the sensitive nature of such discussions, specific counterparties are not named. The company links this expanded outreach to its recently completed equity financings, which it states provide resources to support both business development and R&D expansion.
Role in the Medicinal and Botanical Manufacturing Sector
Within the broader medicinal and botanical manufacturing industry, Lexaria positions itself, through its public statements, as a technology-focused company centered on oral drug delivery improvement rather than on traditional bulk manufacturing of active ingredients. Its emphasis on platform technology, intellectual property, and clinical data suggests a model where value is built around DehydraTECH-enabled formulations and potential collaborations with larger pharmaceutical entities.
For investors and observers, the key elements described by the company include its Nasdaq listing (LEXX and LEXXW), its DehydraTECH drug delivery platform, its ongoing clinical and pre-clinical programs in areas such as GLP‑1 drugs and CBD, its patent portfolio, and its efforts to secure partnerships and funding to support further development.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Lexaria Bioscience Corp. Warrant investment returns
How much was $1,000 invested in Lexaria Bioscience Corp. Warrant worth at its last close?
If you invested $1,000 in Lexaria Bioscience Corp. Warrant (LEXXW) 5 years before its last close, on 2021-01-13, your investment was worth $0.95 on 2026-01-13, a -99.9% price return without dividends, growing at a compounded rate of -75.1% per year (CAGR).
Has Lexaria Bioscience Corp. Warrant outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare LEXXW performance over available time periods.
What is Lexaria Bioscience Corp. Warrant's average annual return?
The compound annual growth rate (CAGR) of LEXXW’s share price over the 5 years to Jan 13, 2026 is -75.1%, without dividends. Individual years vary a great deal, and LEXXW’s best recent full year was 2023 (+12.5%) while the worst was 2022 (-73.3%).
For informational and educational purposes only, not investment advice.